Thoracic Cancer, 2023 Background Triple‐positive breast cancer (TPBC) is highly invasive and lacks well‐established treatment strategies, especially in patients with advanced stage disease.
Yujing Tan +9 more
doaj +1 more source
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma [PDF]
, 2013 This study aimed at determining the recommended dose of the mammalian target of rapamycin inhibitor everolimus in combination with mitomycin C (MMC) in patients with previously treated metastatic esophagogastric cancer.
Atmaca, Akin +5 more
core +1 more source
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
Breast Cancer Research, 2017 Background The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor-positive breast cancer.
Andrew J. Browne +8 more
doaj +1 more source
Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures [PDF]
, 2018 ObjectiveThe present analysis examined the exposure-response relationship by means of the predose everolimus concentration (C-min) and the seizure response in patients with tuberous sclerosis complex-associated seizures in the EXIST-3 study ...
Brandt, Christian +12 more
core +2 more sources
Antibiotics, 2023 Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice ...
Delia Mercedes Bianco +11 more
doaj +1 more source
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. [PDF]
, 2014 BackgroundIn the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone ...
Baselga, J +18 more
core +1 more source
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. [PDF]
PLoS ONE, 2015 Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce.We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients
Lena Caroline Brunkhorst +9 more
doaj +1 more source
Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]
, 2015 BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T +6 more
core +2 more sources
SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
Cancer Biology & Therapy, 2023 Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients.
Wenwen Geng +4 more
doaj +1 more source
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease [PDF]
, 2018 Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in ...
Arcaro, Alexandre +10 more
core +2 more sources